NGNE - Neurogene Inc.
13.05
-2.060 -15.785%
Share volume: 652,573
Last Updated: 05-06-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$15.11
-2.06
-0.14%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-10-2024 | 08-10-2023 | 11-14-2023 | 05-10-2024 | 08-09-2024 | 11-18-2024 | 03-24-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 925.000 K | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 925.000 K | 0.000 | 0.000 | |
| nan% | nan% | nan% | inf% | -100.00% | nan% | |||
| Operating expenses | 13.035 M | 12.596 M | 15.219 M | 18.779 M | 21.059 M | 22.180 M | 21.512 M | |
| Selling general and admin | 2.752 M | 2.275 M | 3.613 M | 5.238 M | 5.315 M | 5.895 M | 6.165 M | |
| Research and development | 10.283 M | 10.321 M | 11.606 M | 13.541 M | 15.744 M | 16.285 M | 15.347 M | |
| Total expenses | 13.035 M | 12.596 M | 15.219 M | 18.779 M | 21.059 M | 22.180 M | 21.512 M | |
| -3.37% | 20.82% | 23.39% | 12.14% | 5.32% | -3.01% | |||
| Operating income | -13.035 M | -12.596 M | -15.219 M | -18.779 M | -20.134 M | -22.180 M | -21.512 M | |
| Ebit | -13.038 M | -12.600 M | -15.223 M | -19.381 M | -20.667 M | -22.199 M | -21.926 M | |
| Pretax income | -12.263 M | -11.860 M | -14.577 M | -17.064 M | -18.636 M | -20.360 M | -19.658 M | |
| -3.29% | 22.91% | 17.06% | 9.21% | 9.25% | -3.45% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -12.263 M | -11.860 M | -14.577 M | -16.921 M | -18.492 M | -20.217 M | -19.514 M | |
| 3.29% | -22.91% | -16.08% | -9.28% | -9.33% | 3.48% |
